

Lung Oncotrail RGCC

Results



Analysis on a patient Jack Black suffering from Lung carcinoma stage II.



The sample that was sent to us for analysis was a sample of 45ml Blood that contains anti-coagulant, and packed with an ice pack.

Laboratory Process

Isolation of malignant cells using flow cytometry with which the circulating tumor cells are enumerated and immunophenotyped

The results during the isolation procedure are presented below

Table of markers

Significant CD45 positive cells (Hematologic origin cells)

Nanog

Positive

OKT-4

Negative

Sox-2

Dim

CD15

Positive

CD45 negative cells (non Hematologic origin)

Nanog

Negative

OKT-4

Dim

Sox-2

Positive (25% of all CTC)

MUC-1

Negative

EpCam

Dim

CD133

Positive (50% of all CTC)

c-MET

Negative

CD31

Dim

PanCK

Positive (75% of all CTC)

SCCA-1

Negative

CD56

Dim

Index of markers

CD133, Sox-2*, OKT-4*, Nanog*

c-MET*

CD34*

CD45

BCR-ABL, CD30

CD44

CD15

CD19

CD31

CD63

CD99

EpCam

MUC-1

PSMA

VHL mut

panCK

Tumor stem cell marker

Membrane antigen that regulates the mesenchymal to epithelial transition

Hematological stem cell and blast cell marker, Epithelioid

Hematologic origin cell

Hematologic malignancy marker

Tumor stem cell marker

Hematological malignancy marker

(CD45 negative cells – Non Hematologic origin cells) Hematological malignancy

(CD45 positive cells – Hematologic origin cells) lung neuroendocrine malignancy

Endothelial cell membrane antigen

Melanoma cell marker

Sarcoma marker

Epithelial origin marker

Breast cancer antigen

Prostate specific cancer stem cell membrane antigen

Renal carcinoma marker

Epithelial origin cell marker

* Significant markers

Ioannis Papatiriu M.D., PhD Head of molecular medicine dpt of R.G.C.C -Research Genetic Cancer Centre International GmbH Baarerstr 95, 6301, Zug, Switzerland

Tel: +41-41-7250560 Website: www.rgcc-group.com E-mail: medical@rgcc-genlab.com

Patient Name: Jack Black

The final results after the isolation procedure are presented below:

We notice that after isolation procedure there are remaining malignant cells.

The concentration of these cells was isolated 4.2 cells/ml, SD +/- 0.3cells.

Index of circulating cells number

If over limit: Advanced or progression of disease. If less than limit: Early disease or disease is responding to a treatment plan.

Breast Cancer

< 5 cells / 7.5 ml

Prostate Cancer

< 20 cells / ml

Sarcoma

< 15 cells / 6.5 ml

Colon Cancer

< 5 cells / ml

Lung Cancer

(Lc=0, r=0.99):< 10 cells / ml

All cancer types other than those listed above should be < 5 cells / ml

Disclaimers

*This test will NOT DETECT cancers of the brain or other cancers that have been "encapsulated" by the body, not releasing circulating tumor or stem cells (CTC, CSC) into the blood stream or if any of these cells are dormant. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist.No test is 100% accurate.

*The methodology has a sensitivity of 86,2% and specificity of 83,9%

Sincerely,



Ioannis Papatiriu MD., PhD Head of molecular medicine dpt. of R.G.C.C.-Research Genetic Cancer Centre International GmbH

Patient Name: Jack Black